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Abstract:
Background: A general non-specific marker of  disease activity that could alert the clinician and prompt further investiga-
tion would be of  value in patients with HIV/AIDS, especially in resource limited environments. 
Objective: To investigate the potential of  neopterin as non-specific biomarker in patients with advanced HIV/AIDS. 
Methods: Cross-sectional study in 105 HIV positive patients (75 on highly active antiretroviral treatment (HAART).  Neop-
terin was assessed by enzyme linked immune-absorbent assay and cytokines by flow cytometry. 
Results: Neopterin levels were significantly higher (p<0.001) for the total patient than for the control group. Significant 
correlations between neopterin and plasma indicators of  inflammation showed neopterin to be a good indicator of  active 
inflammatory status and of  the effect of  HAART on the immune system. Neopterin was superior to C-reactive protein and 
to individual cytokines as indicator of  immune deficiency. Increased neopterin levels were associated with a decline in albu-
min, haemoglobin and the albumin/globulin ratio, and with increases in red cell distribution width.  
Conclusions: Plasma neopterin is a good non-specific biomarker of  disease activity in HIV/AIDS patients. It is a good 
indicator of  inflammatory activity, perpetuation of  inflammation-associated co-morbidities, degree of  immune deficiency 
and has predictive value for underlying disease, and for monitoring the HAART response.
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Introduction 
The search for a suitable biomarker in HIV/AIDS is 
ongoing. Evermore markers are being evaluated as indi-
cators of  immune suppression and disease progression 
and to better understand the immunopathogenesis of  
the disease 1,2.  In contrast to the need for biomark-
ers for specific purposes, a general non-specific marker 
of  disease that could alert the clinician to further in-
vestigate the patient would be of  value, especially in 
resource limited environments. Such a tool should be 
relatively inexpensive and facilities for its determination 
readily available. 
In the present study the suitability of  neopterin as a 
potential non-specific marker of  disease activity is 
examined. Neopterin, a catabolic product of  the pu-
rine nucleotide guanosine triphosphate, is produced 
from guanosine 5'-triphosphate (GTP) that is cleaved 
by GTP- cyclohydrolase 1 to 7,8-dihydroneopterin 
triphosphate, followed by  conversion of  7,8-dihydro-
neopterin triphosphate to neopterin and 7,8-dihydrone-
opterin under the influence of  phosphatases3. GTP-cy-
clohydrolase 1 is stimulated, predominantly, by T-helper 
cell type-1 derived interferon-γ but co-stimulation by 
tumour necrosis factor alpha may contribute3. 
The value of  neopterin as non-specific indicator was 
examined in terms of  its potential as indicator of  in-
flammatory status, as indicator of  immune deficiency or 
dysfunction, the effects of  anti-retroviral treatment and 
as indicator of  TB co-infection. In these assessments 
the efficacy of  neopterin was validated by comparison 
with immune-related factors such as the acute phase 
protein C-reactive protein (CRP), CD4 counts, as well 
as pro- and anti-inflammatory cytokines. In addition, 
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neopterin levels were compared to that of  a number of  
factors routinely measured for diagnostic purposes and 
elsewhere described as biomarkers. 
 
Methods
Study population and ethics statement
This was a cross-sectional, non-intervention study 
comprising of  105 HIV positive adult patients recruit-
ed from the Kalafong secondary hospital in Pretoria, 
South Africa, and a control group of  60  donors from 
the South African National Blood Service who tested 
HIV negative and were therefore considered HIV un-
infected. A total of  75 patients were on antiretroviral 
therapy (HAART group) and 30 patients were HAART-
naïve. Ethical clearance,  in accordance with the dec-
laration of  Helsinki, the National Health Act and the 
policy of  the University, was received from the Faculty 
of  Health Sciences Research and Ethics Committee of  
the University of  Pretoria (Number: 107/2008). The 
committee also approved the documentation used for 
obtaining either written or verbal voluntary informed 
consent prior to the study. Participants who could not 
read or write were informed by a clinician about the 
nature and purpose of  the study before verbal consent 
was obtained. Verbal consent was documented under 
the relevant section on the consent form which was ac-
knowledged and signed by the clinician and investigator.
Cytokine and neopterin assays
Plasma neopterin was measured by commercial enzyme 
linked immune-absorbent assay (Immuno-Biological 
Laboratories Inc., USA). The cytokines IL-2, IL-4, IL-
6, IL-10, TNF and IFN-γ were measured in plasma 
by cytometric bead array (CBA) kit protocol (BD Bio-
sciences, San Jose, CA, USA) using flow cytometry. The 
CBA cytokines were analysed on a FACS Array Bioana-
lyzer using FCAP FCS Filter and FCAP Array software 
(BD Biosciences, USA). Routine blood variables were 
analysed by the National Health Laboratory Service 
(NHLS) at Kalafong. 
Statistical analyses
The data was first tested for normality, followed by log 
transformation as the raw data was not normally dis-
tributed. Transformed data were analysed using one 
way analysis of  variance (ANOVA) for comparison be-
tween groups. Pairwise comparisons were undertaken 
by Tukey HSD and Scheffe methods. Spearman rank 
correlations were computed to determine associations 
between group variables. Area under the ROC curve 
(AUROC) values were determined using logistic regres-
sion and CD4 cut-offs of  less than 200 cells/µl. Anal-
yses were performed at a significance level of  p<0.05 
using STATA statistical analysis software (version 12.1).
 
Results 
The suitability of  neopterin as a general non-specific 
marker of  disease activity in HIV/AIDS patients was 
examined in a group of  105 HIV/AIDS (HIV-1) pa-
tients with a mean viral load of  2.75 ± 1.36 log10 cop-
ies/ml and a CD4 count of  257.97 ± 193.06 cells/µl. 
The demographic information of  the study subjects 
can be seen in Table 1.
Table 1 Demographic information for the patient and control groups 
 HAART HAART-naïve Controls 
n  75 30 60 
Females 48 (64%) 18 (60%) 38 (63%) 
Age (years) 37.86±8.86  37.13±10.24 31.18±8.09 
BMI (kg/m2) 23.83±6.31 20.96±3.62 21.96±4.81 
Average months on HAART 15.86±16.49 - - 
TB co-infection at baseline 14 (19%) 10 (33%) - 
 
CRP, cytokines and CD4 counts were employed in the 
appraisal of  neopterin as non-specific biomarker of  the 
inflammatory status, immune deficiency, the effects of  
anti-retroviral treatment and TB co-infection. The cy-
tokines included the pro-inflammatory cytokines IL-2, 
IL-6, TNF and IFN-γ, as well as the anti-inflammatory 
cytokines IL-4 and IL-10. A comparison between the 
total patient group, the group on HAART, the HAART-
naïve and the control group levels of  immunological 
factors can be seen in Table 2. 
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Table 2 Comparison of immunological and other variables between the controls and patient 
groups 
Variable Controls Total Patients HAART HAART-Naïve p-value 
 C T H N T vs. C H vs. C N vs. C H vs. N 
IL-2 (pg/ml) 9.14±2.26 20.06±8.31 18.95±8.41 22.74±7.53 <0.0001 0.0003 <0.0001 0.076 
IL-4 (pg/ml) 8.07±2.01 11.96±4.01 11.65±4.16 12.70±3.40 <0.0001 <0.0001 <0.0001 0.198 
IL-6 (pg/ml) 0.69±1.62 11.16±14.95 9.56±12.54 15.04±19.34 0.0001 0.035 0.001 0.010* 
IL-10 (pg/ml) 1.45±1.32 14.61±12.53 12.44±12.38 19.82±11.51 <0.0001 <0.0001 <0.0001 0.026* 
TNF (pg/ml) 1.71±1.78 5.74±3.68 5.65±3.89 5.95±3.19 <0.0001 0.0002 <0.0001 0.473 
IFN-γ (pg/ml) 24.85±2.96 44.00 ± 22.55 41.43±14.14 53.68±34.39 <0.0001 0.0003 <0.0001 0.017* 
NPT (nmol/l) 8.23±5.71 45.57±41.82 34.51±35.70 66.63±40.73 <0.0001 <0.0001 <0.0001 0.0001* 
NPT/IL-4 1.04±0.75 3.81±3.74 3.04±3.34 5.63±4.05 0.001 0.02 0.0001 0.002* 
IL-2/IL-4 1.15±0.26 1.68±0.76 1.59±0.64 1.90±0.97 <0.0001 0.001 0.0007 0.058 
IL-6/IL-4 0.06±0.14 0.86±1.17 0.74±1.05 1.16±1.39 <0.0001 0.001 0.0065 0.102 
IFN-γ/IL-4 3.25±1.02 3.97±3.01 3.59±1.26 4.87±5.12 0.030 0.019 0.009 0.050 
CRP (mg/l) - 25.93±51.23 22.88±36.13 34.08±75.78 - - - 0.839 
CD4 (cells/µl) - 257.97±193.06 296.21±195.50 170.05±167.26 - - - 0.003* 
VL (log10 copies/ml) - 2.75±1.36 2.48±1.12 3.57±1.71 - - - 0.014* 
Albumin (g/l) - 33.40±7.55 34.94±6.67 29.50±8.37 - - - 0.027* 
A/G ratio - 0.68±0.25 0.73±0.24 0.53±0.21 - - - 0.004* 
Haemoglobin (g/dl) - 11.83±2.36 12.16±2.36 10.97±2.05 - - - 0.125 
RDW (%) - 17.45±4.35 17.52±4.50 17.28±4.01 - - - 0.334 
Data expressed as mean±SD; IL = Interleukin; TNF = tumor necrosis factor; IFN = interferon; NPT = neopterin; VL = HIV viral 
load; A/G = albumin to globulin ratio; RDW = red cell distribution width 
*p<0.05 for HAART vs. HAART-naïve  
The validity of  neopterin as indicator of  immune de- ficiency was tested against CD4 counts, CRP and cy-
tokine levels. The results can be seen in Table 3.
Table 3 Correlations of neopterin with CD4 counts, CRP, IL-6, albumin, A/G ratio, 
haemoglobin and red cell distribution width 
Neopterin with: 
Total Patients HAART HAART-Naïve 
Rho p-value Rho p-value Rho p-value 
CD4 -0.484 0.0001* -0.43 0.001* -0.503 0.02* 
IL-6 0.371 0.0010* 0.490 0.00001* 0.128 0.510 
CRP 0.355 0.0006* 0.610 0.00001* 0.180 0.597 
IFN-γ 0.301 0.002* 0.277 0.017* 0.216 0.260 
Albumin -0.547 0.0001* -0.447 0.0002* -0.457 0.014* 
A/G ratio -0.489 0.00001* -0.423 0.0004* -0.373 0.061 
Haemoglobin -0.597 0.00001* -0.555 0.00001* -0.33 0.093 
RDW 0.342 0.001* 0.472 0.0001* 0.112 0.577 
*Spearman Rho rank correlation statistically significant, p<0.05. IL = interleukin; CRP = C-reactive 
protein; IFN = interferon; A/G ratio = albumin/globulin ratio; RDW = red cell distribution width 
The power of  discrimination, in terms of  area under 
the ROC curve (AUROC), of  neopterin, CRP and IL-6 
was also tested for the total patient group in relation to 
CD4 counts of  less than 200 using logistic regression. 
The discriminatory power of  neopterin (AUROC = 
0.803) was found to be higher than that for CRP (AU-
ROC = 0.658), and for IL-6 (AUROC = 0.753). 
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Twenty four of  the total HIV patient group were con-
firmed as having tuberculosis (TB) co-infection (spu-
ta smears). Neopterin (p=0.008) and CRP (p=0.004) 
levels were both significantly higher in the HIV/TB 
positive group (neopterin: 65.73±48.94 nmol/l; CRP: 
47.35±57.12 mg/l) than in the HIV/TB negative group 
(neopterin: 37.37±34.48 nmol/l; CRP: 18.99±47.56 
mg/l).
The discriminatory power for neopterin (AUROC = 
0.898) was higher than that for CRP (AUROC=0.6252) 
for the TB-co-infection group. Likewise neopterin 
(AUROC = 0.7367) showed to be a better discrimina-
tor than CRP (AUROC = 0.5945) for the TB-negative 
patients.
Substances routinely measured in the clinic and previ-
ously described as biomarkers, i.e., albumin, the albu-
min/globulin (A/G) ratio, haemoglobin and red cell 
distribution width (RDW) were evaluated as indicators 
of  immune deficiency by comparing their levels to CD4 
counts. The results can be seen in Table 4.
Table 4 Correlations for CD4 with blood variables of the different groups 
CD4 with: 
Total Patients HAART Naïve 
Rho p-value Rho p-value Rho p-value 
IL-6 -0.431 0.0001* -0.553 0.009* -0.285 0.193 
CRP -0.328 0.007* -0.410 0.005* -0.250 0.287 
Albumin 0.491 0.00001* 0.497 0.0004* 0.142 0.551 
A/G ratio 0.486 0.00001* 0.505 0.0003* 0.113 0.636 
Haemoglobin 0.420 0.0003* 0.392 0.004* 0.256 0.276 
RDW -0.370 0.010* -0.470 0.0004* 0.017 0.942 
*Spearman Rho rank correlation statistically significant, p<0.05. IL = interleukin; CRP = C-reactive 
protein; A/G ratio = albumin/globulin ratio; RDW = red cell distribution width 
Logistic regression results in a comparison between 
neopterin, albumin, the AG/ratio, haemoglobin and 
RDW as indicators of  immune deficiency were: neop-
terin (AUROC = 0.803), albumin (AUROC = 0.487), 
the A/G ratio (AUROC = 0.504), haemoglobin (AU-
ROC = 0.334) and RDW (AUROC = 0.589).
 
Discussion
The value of  neopterin as non-specific indicator was 
examined in terms of  its potential as indicator of  in-
flammatory status, the effects of  anti-retroviral treat-
ment, as indicator of  immune deficiency or dysfunction 
and as indicator of  TB co-infection. The validity of  ne-
opterin as non-specific biomarker in HIV/AIDS was 
compared to that of  CRP, cytokines and to a number of  
substances routinely measured in the clinic.
Neopterin as indicator of  inflammatory (cellular 
immunity) status in HIV AIDS
Advanced HIV/AIDS is characterised by chronic im-
mune activation and a concomitant immune deficien-
cy. Although the levels of  pro-inflammatory, as well as 
anti-inflammatory, cytokines may be raised5, advanced 
HIV/AIDS is predominantly associated with increased 
inflammatory activity6,7. The inflammatory process is 
implicated as a major contributor to the pathogenesis 
of  many physical disorders, and is likely to play a role 
in the cardiovascular, renal, liver, metabolic, haemato-
logical and skeletal abnormalities, as well as the prema-
ture systemic aging associated with HIV infection6,7. 
Increased inflammatory activity is similarly linked to 
neuropsychological impairments8, including that found 
in HIV/AIDS 9,10.
Neopterin levels are generally considered as an indica-
tion of  both macrophage function and cell mediated 
immunity. It is said that when cell-mediated immunity 
dominates, circulating neopterin levels are usually high 
and when humoral immunity dominates, neopterin lev-
els are low3-11. Abundant evidence exists for neopterin 
levels to be increased in disturbances marked by in-
flammatory activity and raised neopterin levels and in-
creases with disease progression, have previously been 
described12. However, other substances, in particular 
CRP and IL-6, have also been described as markers of  
inflammation. 
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In the present study the value of  neopterin as gener-
al marker of  the inflammatory status was examined by 
comparing neopterin levels to that of  two other rec-
ognised biomarkers of  inflammation, i.e., CRP and 
IL-66,11-13. As seen in Table 2, the mean neopterin lev-
els were significantly higher than that of  the control 
group for both the HAART-naïve (p<0.001) and the 
HAART (p<0.001) groups. IL-6 levels were also sig-
nificantly higher than that of  the control group for 
the HAART naïve (p=0.001) and the HAART groups 
(p=0.035). CRP and IL-6 levels correlated positively 
with that of  neopterin for the total patient group (CRP: 
r=0.355, p=0.0006; IL-6: r=0.371, p=0.001) and for 
the HAART group (CRP: r=0.61, p<0.00001; IL-6: 
r=0.49, p<0.0001) (Table 3). These results supported 
the notion of  neopterin as the better marker of  inflam-
matory activity and are in agreement with the concept 
of  advanced HIV/AIDS as a condition with increased 
inflammatory activity 6,7.
 
However, although higher pro-inflammatory activity 
was confirmed in the patients, higher than control lev-
els (p<0.05) were, as reported elsewhere5, also seen in 
the levels of  the anti-inflammatory cytokines (Table 2). 
Nevertheless, when the pro- versus anti-inflammatory 
activity was investigated it was found that the ratio ne-
opterin/IL-4 was indeed higher in the HAART-naïve 
(p=0.0001), as well as in the HAART patients (p=0.02), 
than in the controls. This imbalance with a shift to-
wards inflammation in HIV/AIDS was confirmed by 
the ratios of  the individual pro-inflammatory cytokines 
to that of  the anti-inflammatory cytokine IL-4. Signifi-
cantly higher than control ratios were seen for IL-2/IL4 
(HAART: p=0.001; HAART-naïve: p=0.0007), IL-6/
IL4 (HAART: p=0.001; HAART-naïve: p=0.0065), 
as well as for IFN/IL4 (HAART: p=0.019; HAART-
naïve: p=0.009). 
Pro-inflammatory dominance with cell-mediated im-
munity in ascendancy was thus shown in the group on 
anti-retroviral therapy, as well as in the group not yet 
on anti-retroviral therapy. Such inflammatory activity, 
demonstrated here by neopterin levels and confirmed 
by cytokine results, is implicated in the pathogenesis of  
HIV/AIDS6,7.
Effect of  HAART on the pro-inflammatory/an-
ti-inflammatory (cellular/humoral immune) status
The mean neopterin level in the HAART group was 
48% lower (p=0.0001) than that of  the HAART-naïve 
group, the mean IL-6 level was 43% lower (p=0.01), the 
mean IFN-γ was 22.8% lower (p=0.017), the mean IL-2 
was 16.7% lower (p=0.076) and the CRP level, although 
not statistically significant, was 33% lower.  However, 
the HAART group still showed significantly higher in-
flammatory activity than the control group. In contrast, 
the levels of  the anti-inflammatory cytokine, IL-4, were 
not significantly different between the HAART and 
HAART-naïve groups (Table 2). These results, which 
demonstrated a down-regulation of  neopterin and 
therefore in inflammatory activity upon treatment with 
highly active antiretroviral treatment are in agreement 
with that of  Amirayan-Chevillard et al14. Amirayan-Che-
villard et al further showed that neopterin levels again 
increase with cessation of  antiretroviral treatment14, a 
finding that implies neopterin to be a useful marker of  
the efficacy of  HAART and perhaps for the assessment 
of  patient compliance. 
As an imbalance between pro- and anti-inflammatory 
activity, in favour of  pro-inflammatory, has previously 
been implicated in the pathogenesis of  HIV/AIDS7, it 
was of  interest to see to what extent this imbalance was 
corrected by antiretroviral treatment. The ratio between 
neopterin and the main anti-inflammatory cytokine 
IL-4 for HAART  was significantly lower (p=0.002) 
than that for the HAART-naïve patients – pointing to 
suppression of  cellular (pro-inflammatory) relative to 
humoral (anti-inflammatory) activity by antiretroviral 
treatment. However, the ratio in the HAART group was 
still higher (p=0.02) than in the control group, confirm-
ing the persistence of  a shift towards pro-inflammatory 
activity despite anti-retroviral treatment (Table 2).  Al-
though the ratios of  all the individual pro-inflammatory 
cytokines to the level of  the anti-inflammatory cytokine 
IL-4 (IL-2/IL-4, IL-6/IL-4, IFN-γ /IL-4) were also 
lower in the HAART than in the HAART-naïve group, 
none were significantly lower.
This persistent, albeit downgraded, presence of  inflam-
matory, and imbalance between pro- and anti-inflam-
matory activity, despite effective antiretroviral therapy, 
has previously been reported and is described as a ma-
jor contributor to the perpetuation of  non-AIDS de-
fining co-morbidities and premature systemic aging in 
patients on HAART7. Among the best known contribu-
tors to such persistence are said to be clinical or subclin-
ical infections, gastrointestinal microbial translocation, 
infectious, as well as non-infectious, HIV virions and 
thymic dysfunction7.
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Neopterin as indicator of  immune deficiency
Neopterin has previously been shown as a measure of  
the degree of  immune deficiency in HIV/AIDS pa-
tients2,15,16. In the present study the potential of  neop-
terin as indicator of  immune deficiency was again inves-
tigated by comparing neopterin levels to that of  CD4 
counts. Results with neopterin were then compared to 
that with CRP and cytokines.
Negative correlations were found between neopter-
in levels and CD4 counts for the total patient group 
(r=-0.484, p=0.0001), the HAART group (r=-0.43, 
p=0.001) and the HAART-naïve group (r=-0.503, 
p=0.02) (Table 3). 93.3% of  the HAART-naïve patients 
and 73.3% of  the HAART patients had higher than 
normal neopterin levels. These results, which suggest 
neopterin as an indicator of  immune deficiency, are in 
line with that of  previous publications 2,15,16.
Neopterin was subsequently compared to CRP and 
cytokines as immune deficiency indicators. CRP and 
one of  the cytokines investigated, that is, IL-6, showed 
significant negative correlations with CD4 counts for 
the total patient group (CRP: r=-0.328, p=0.007; IL-6: 
r=0.431, p=0.0001) and the HAART group (CRP: r=-
0.410, p=0.005; IL-6: r=-0.553, p=0.009), but not for 
the HAART-naïve group (Table 4). In contrast to ne-
opterin, only 49.3% of  the HAART-naïve patients and 
46.7% of  the HAART patients had higher than normal 
CRP reference levels.  83.3% of  the HAART-naïve pa-
tients and 65.3% of  the HAART patients had higher 
than normal IL-6 levels. 
Logistic regression showed the discriminatory power 
of  neopterin (AUROC = 0.803) to be higher than that 
for CRP (AUROC = 0.658), and for IL-6 (AUROC = 
0.753).  Neopterin was therefore shown to be superior 
to CRP and to individual cytokines as indicator of  im-
mune deficiency.
Neopterin and HIV/AIDS with TB-co infection
Neopterin levels are known to be significantly higher 
in individuals with active tuberculosis than in patients 
with inactive tuberculosis or controls17.  It would thus 
seem feasible to expect that HIV/AIDS patients with 
TB-co-infection would have higher levels of  neopterin 
than HIV patients without TB-co-infection. The abili-
ty of  neopterin to discriminate between HIV patients 
with and without active TB was therefore investigated 
and compared to that of  CRP and cytokines.
Neopterin (p=0.008) and CRP (p=0.004) levels were 
both significantly higher in the 24 HIV/TB posi-
tive than in the HIV/TB negative patients. This is in 
agreement with previous reports9. Logistic regression 
analysis showed the discriminatory power for neopter-
in (AUROC = 0.898) to be higher than that for CRP 
(AUROC=0.6252). Neopterin therefore seems to be 
the better indicator of  TB-co-infection in patients with 
HIV/AIDS. 
Previous indications that cytokines such as IFN-γ, 
TNF-alpha, IL-6, IL-10 and the IFN/IL-10 ratio may 
be of  diagnostic/prognostic value in TB19-24 were not 
substantiated by the results of  the present study. In 
contrast to our expectations that the balance between 
pro- and anti-inflammatory activity would be more un-
favourable with TB-co-infection, the difference for the 
neopterin/IL-4 ratio between patients with and without 
TB co-infection (p=0.059) was non-significant when 
judged at a 0.05 level of  significance. 
Advantage of  neopterin above that of  the measure-
ment of  individual cytokines 
Locally produced cytokines could bind to their target 
tissues or be neutralized by soluble receptors25. Cy-
tokine release may therefore not be accurately reflected 
by circulating levels. The circulating level of  neopterin, 
on the other hand, is largely a product of  the balance 
between synthesis and renal excretion15. It therefore 
speaks for itself  that neopterin could very well be a 
better biomarker than individual cytokines. In addition, 
because of  the pleiotropic nature of  cytokines as well as 
the multiple interactions and co-operations between cy-
tokines, the measurement of  one specific cytokine may 
not reflect its contribution to inflammation and other 
immune processes. Neopterin is said to reflect the mul-
tiple cooperations between immunocompetent cells26.
Comparison of  neopterin levels to that of  circulat-
ing substances and ratios elsewhere described as 
biomarkers in HIV/AIDS patients 
Albumin concentration, the albumin/globulin (A/G) 
ratio, red cell distribution width (RDW) and haemoglo-
bin (Hb) concentration are routinely measured during 
clinical investigations. Yet they have elsewhere all been 
described as biomarkers of  disease progression and/or 
immune deficiency, in general, as well as in HIV/AIDS 
27-32. 
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Previous associations shown between immune deficien-
cy (decreased CD4 counts) with albumin, A/G ratios, 
haemoglobin and RDW, respectively27-32, were support-
ed by results on the total patient and HAART groups of  
the present study (Table 4). Positive correlations were 
found between albumin and the CD4 counts for the 
total patient group (r=0.491, p=0.00001) and the group 
on HAART (r=0.497, p=0.0004). Positive correlations 
were also found between the A/G ratio and the CD4 
counts for the total patient group (r=0.486, p=0.00001) 
and the group on HAART (r=0.505, p=0.0003). Haemo-
globin concentration correlated positively with the CD4 
count for the total patient group (r=0.42, p=0.0003) 
and for the HAART group (r=0.392, p=0.004). RDW 
correlated negatively with the CD4 count for the to-
tal patient group (r=-0.37, p=0.010) and the group on 
HAART (r=-0.47, p=0.0004). 
It is known that the levels of  albumin, A/G ratios, hae-
moglobin and RDW are all adversely influenced by in-
flammation. With chronic inflammation the levels of  
albumin, a negative acute-phase protein, decreases as a 
result of  lower synthesis, an increase in fractional meta-
bolic rate, appetite suppression and through an increase 
in microvascular albumin leakage33,34. Chronic inflam-
matory conditions can influence haemoglobin levels, 
RDW and other red blood cell parameters in various 
ways, most notably processes involved in the anaemia 
of  chronic disease35. The association between RDW 
and inflammation is so strong that RDW has been de-
scribed as indicative of  inflammation36.
In the present study negative correlations between ne-
opterin and albumin concentrations were observed for 
the total patient group (r=-0.547, p=00001), the group 
on HAART (r=-0.447, p=0.0002) and the HAART-
naïve group (r=-0.475, p=0.014). As for albumin, the 
A/G ratio declined with increases in neopterin as seen 
in the negative correlations for the total patient group 
(r=-0.489, p=0.00001), the HAART group (r=-0.423, 
p=0.0004) and the HAART-naïve group (r=-0.373, 
p=0.061). Negative correlation were also found be-
tween the haemoglobin and neopterin levels for the 
total patient group (r=-0.597, p=0.00001) and for the 
HAART group (r=-0.555, p=0.00001), while for the 
HAART-naïve group only a weak negative correlation 
was found (r=-0.33, p=0.093). Significant positive cor-
relations were found between RDW and neopterin for 
the total patient group (r=0.342, p=0.001) and for the 
HAART group (r=0.472, p=0.0001). In line with previ-
ous publications, the present study thus demonstrated 
a decline in the levels of  albumin, the A/G ratio and 
haemoglobin concentrations, and an increased RDW, 
with increases in inflammatory activity, as reflected by 
neopterin levels.
Although albumin, the A/G ratio, haemoglobin and 
RDW were seen to have a positive association with the 
degree of  immune deficiency, neopterin (AUROC = 
0.803) was shown to be a better indicator of  immune 
deficiency than albumin (AUROC = 0.487), the A/G 
ratio (AUROC = 0.504), haemoglobin (AUROC = 
0.334) and the RDW (AUROC = 0.589).
Additional reasons why neopterin could be a good 
non-specific biomarker in HIV/AIDS patients 
In addition to evidence of  neopterin as a good non-spe-
cific marker of  disease, as shown in our study, various 
other phenomena support this assumption. The value 
of  neopterin as indicator of  disease progression in HIV 
has been shown by several laboratories16, and in an ear-
lier paper on HIV/AIDS patients of  African ethnicity 
we showed neopterin to be superior to CRP and pro-
calcitonin as indicator of  disease progression2. Another 
connection between neopterin levels and disease is sug-
gested by the correlation between neopterin and IFN-γ 
(Table 3). IFN-γ is the major factor responsible for a 
shift in tryptophan metabolism towards the kynurenine 
pathway37. Abnormalities in tryptophan metabolism 
can have a widespread influence on both physical and 
psychological well-being. In the present study signifi-
cant positive correlations were found between neopter-
in levels and the levels of  IFN-γ (total patient group: 
r=0.301, p=0.002; HAART: r=0.277, p=0.017). A fur-
ther potential link between neopterin levels and disease 
activity in HIV/AIDS lies in the production of  reac-
tive oxygen species (ROS). Excessive ROS is known to 
contribute to the pathogenesis of  HIV/AIDS and cor-
relations have been shown to exist between neopterin 
levels, increased production of  ROS and decreased cir-
culating antioxidants38-41. Other associations, not to be 
discussed here exist, such as that between neopterin and 
upregulation of  the expression of  the proto-oncogene 
c-fos42, the nuclear factor-кB41, and the iNOS gene43. 
However, the primary association is probably that be-
tween neopterin and inflammation.
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Conclusions
This study in HIV/AIDS patients showed neopterin to 
be a better indicator of  the inflammatory status, immune 
deficiency, TB-co-infection and the effects of  HAART 
than CRP or cytokines. Changes in plasma neopterin 
levels as an indication of  the efficacy of  HAART or 
of  patient compliance, should be investigated further. 
In line with the effects of  inflammation on various sys-
tems, neopterin levels reflect the negative effects of  the 
disease on levels of  albumin, haemoglobin, the albu-
min/globulin ratio and the red cell distribution width.  
It is our contention that neopterin levels represent a 
good non-specific indicator, not only of  inflammato-
ry activity, but of  the general health status. This state-
ment is made in view of  its associations with inflam-
mation, the effects of  HAART, immune deficiency, 
TB-co-infection, the levels of  several plasma proteins 
and, as previously reported, disease progression. The 
statement is further supported by previously supported 
diagnostic and prognostic associations between plasma 
neopterin levels and disorders other than HIV/AIDS. 
These include viral, intracellular bacterial and parasitic 
infections, burns, cancer, cardiovascular disease, neu-
rodegeneration, graft versus host disease, autoimmune 
disorders and a variety of  oral afflictions12.  However, in 
view of  the effect of  inflammation on all physiological 
systems, the primary importance of  neopterin probably 
lies in its reflection of  the degree of  inflammation, a 
major contributor to the pathogenesis of  HIV/AIDS 
and a process involved in a wide variety of  pathological 
processes. The skills required for the analysis of  neop-
terin fall within that of  most trained laboratory analysts 
and the costs are below that of  the more specialized 
techniques. Neopterin therefore offers a relatively inex-
pensive non-specific biomarker in resource limited en-
vironments to alert the clinician to investigate further..
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